| abstract |
A compound of formula (I) wherein R 1 represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group —(CH 2 ) m -T-(CH 2 ) n —U—(CH 2) p — is attached at either the 3 or 4 position in the phenyl ring as indicated by the numbers in formula (I) and represents a group selected from one or more of the following: O(CH 2 ) 2 , O(CH 2 ) 3 , NC(O)NR 4 (CH 2 ) 2 , CH 2 S(O 2 )NR 5 (CH 2 ) 2 , CH 2 N(R 6 )C(O)CH 2 , (CH 2 ) 2 N(R 6 )C(O)(CH 2 ) 2 , C(O)NR 7 CH 2 , C(O)NR 7 (CH 2 ) 2 , and CH 2 N(R 6 )C(O)CH 2 O; V represents O, S, NR 8 or a single bond; q represents 1, 2, or 3; W represents O, S, N(R 9 )C(O), NR 10 , or a single bond; R 2 represents halo, a C 1-4 alkyl group which is optionally substituted by one or more fluoro, a C 1-4 alkoxy group which is optionally substituted by one or more fluoro, a C 1-4 acyl group, aryl, an aryl C 1-4 alkyl group, CN or NO 2 ; r represents 0, 1, 2 or 3; R 3 halo, a C 1-4 alkyl group which is optionally substutited by one or more fluoro, a C 1-4 alkoxy group which is optionally substituted by one or more fluoro, a C 1-4 acyl group, aryl, an aryl C 1-4 alkyl group, or CN; s represents 0, 1, 2 or 3; and R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 independently represent H, a C 1-10 alkyl group, aryl or an aryl C 1-4 alkyl group or when m is O and T represents a group N(R 6 )C(O) or a group (R 5 )NS(O 2 ) then R 1 and R 6 or R 1 and R 5 together with the nitrogen atom to which they are attached represent a heteroaryl group; with provisos and pharmaceutically acceptable salts thereof, processes for preparing such compounds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them. |